Dolby Laboratories (NYSE:DLB – Get Free Report) updated its fourth quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 1.130-1.280 for the period, compared to the consensus estimate of 1.160. The company issued revenue guidance of $362.0 million-$392.0 million, compared to the consensus revenue estimate of $351.1 million. Dolby Laboratories also updated its FY 2026 guidance to 4.250-4.400 EPS.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. Rosenblatt Securities reiterated a “buy” rating and set a $85.00 target price on shares of Dolby Laboratories in a report on Thursday, June 11th. Barrington Research reissued an “outperform” rating and issued a $90.00 price target on shares of Dolby Laboratories in a report on Monday, June 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Dolby Laboratories in a research report on Wednesday, June 24th. Finally, Wall Street Zen raised Dolby Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $90.75.
View Our Latest Stock Analysis on DLB
Dolby Laboratories Stock Down 1.6%
Dolby Laboratories (NYSE:DLB – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The electronics maker reported $0.69 EPS for the quarter, topping the consensus estimate of $0.67 by $0.02. The firm had revenue of $305.00 million during the quarter, compared to analyst estimates of $311.96 million. Dolby Laboratories had a net margin of 17.85% and a return on equity of 11.47%. Dolby Laboratories has set its FY 2026 guidance at 4.250-4.400 EPS and its Q4 2026 guidance at 1.130-1.280 EPS. On average, sell-side analysts expect that Dolby Laboratories will post 3.21 earnings per share for the current year.
Insider Activity at Dolby Laboratories
In related news, SVP Shriram Revankar sold 3,000 shares of Dolby Laboratories stock in a transaction on Friday, May 15th. The stock was sold at an average price of $54.90, for a total value of $164,700.00. Following the transaction, the senior vice president owned 80,603 shares in the company, valued at approximately $4,425,104.70. This trade represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP John D. Couling sold 7,667 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.20, for a total value of $407,884.40. Following the sale, the senior vice president directly owned 118,727 shares of the company’s stock, valued at approximately $6,316,276.40. This trade represents a 6.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 47,458 shares of company stock valued at $2,639,537 over the last quarter. 37.93% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Dolby Laboratories
Several hedge funds and other institutional investors have recently modified their holdings of DLB. EP Wealth Advisors LLC acquired a new stake in Dolby Laboratories during the 4th quarter worth approximately $231,000. Cresset Asset Management LLC lifted its position in Dolby Laboratories by 10.7% during the third quarter. Cresset Asset Management LLC now owns 2,991 shares of the electronics maker’s stock valued at $216,000 after buying an additional 290 shares in the last quarter. Fieldview Capital Management LLC acquired a new position in Dolby Laboratories during the fourth quarter valued at approximately $206,000. B. Riley Wealth Advisors Inc. purchased a new stake in Dolby Laboratories during the second quarter worth approximately $206,000. Finally, Fiduciary Trust Co acquired a new stake in shares of Dolby Laboratories in the third quarter worth $201,000. 58.56% of the stock is owned by institutional investors and hedge funds.
About Dolby Laboratories
Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.
Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.
Featured Stories
- Five stocks we like better than Dolby Laboratories
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
